INTELLIA THERAPEUTICS INC · held by 2 funds · data as of 2026-06-03
Sector
Healthcare
Industry
Biotechnology
Market cap
$1.83B
Price
$12.99
12-mo
+60.60%
Held by
2 funds
Intellia Therapeutics, Inc. operates as a clinical-stage genome editing company focused on developing potentially curative therapeutics using CRISPR/Cas9-based technologies. The company offers clustered, regularly interspaced short palindromic repeats (CRISPR)/CRISPR associated 9 (Cas9) technology for genome editing. The company provides a modular platform, to advance in vivo and ex vivo therapies for diseases. The company's in vivo product candidates include nexiguran ziclumeran, or NTLA-2001 for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary ang…